News

Drs. Dawn Hershman and Primo Lara elected group co-chairs-elect of SWOG Cancer Research Network

SWOG researchers report results in rare gynecologic cancers from S1609 DART immunotherapy trial

SWOG S1512 trial sees high response rate to pembrolizumab in patients with unresectable desmoplastic melanoma

SWOG S2302 Pragmatica-Lung study opens to enrollment, a model for easier, more representative clinical trials

S1416 trial results show PARP inhibitor benefit in "BRCA-like" triple-negative breast cancer

Nab-paclitaxel does not extend biliary tract cancer survival, but may benefit some

Four decades of NCI-funded NCTN trials gave U.S. patients 14.2 million life-years for a federal investment of $326 per life-year gained

Patients with high-risk melanoma had better quality of life on pembrolizumab than on standard immunotherapy regimens

SWOG researchers will present 10 abstracts at SABCS 2022. Here are highlights.